Meridian Bioscience reported $28.75M in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbott ABT:US $ 2447M 458M
Accelerate Diagnostics AXDX:US -14185000 8.62M
Atrion ATRI:US 8.13M 150K
Becton, Dickinson and BDX:US $ 454M 223M
Bio Rad Laboratories BIO:US $ -3369.61M 1795.95M
Cerulean Pharma CERU:US $ -8.4M 1.14M
Cerus CERS:US $ -12.28M 3.16M
Meridian Bioscience VIVO:US $ 28.75M 13.41M
Myriad Genetics MYGN:US $ -20.5M 12.9M
Orasure Technologies OSUR:US $ -19.97M 9.57M
Quidel QDEL:US $ 479.94M 188.62M
Sientra SIEN:US $ -18.04M 1.97M
Staar Surgical STAA:US $ 9.6M 4.68M
Thermo Fisher Scientific TMO:US $ 2215M 557M
Utah Medical Products UTMD:US 4.21M 1.18M